MD Anderson, Exscientia collaborate to develop oncology treatments using AI

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD Anderson Cancer Center and Exscientia plc formed a strategic collaboration to align the drug discovery and development expertise of MD Anderson with the patient-centric artificial intelligence capabilities of Exscientia in order to advance novel small-molecule oncology therapies.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login